Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)
Key Information
Due Date: December 7, 2024
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: $581,371
Funding Type: Grant
Match Required: No
Status: Posted
Contact Info:
OERWebmaster03@od.nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
This summarized text is about a grant called 'Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)'. The aim of this Funding Opportunity Announcement (FOA) is to financially support research that proposes assumptions on transgender people. The targeted research focuses on understanding the biological and immunological effects of various interventions used in gender reassignment, like hormone treatments, drugs, and surgery. Specifically, the research aims to delve into the resultant impact of these interventions on the susceptibility of transgender individuals to HIV and other sexually transmitted infections (STIs). This grant opportunity does not permit R21 Clinical Trials.
Show More
Key Dates
Open Date: May 19, 2022
Application Due Date: December 7, 2024
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses